Page 157 - 南京医科大学自然版
P. 157

第46卷第5期         卢森威,彭红红,施 超. 呼吸道合胞病毒(A/B亚型)人群抗体特征及影响因素研究进展[J].
                  2026年5月                    南京医科大学学报(自然科学版),2026,46(5):771-779,784                      ·779 ·


                    review and meta ⁃ analysis[J]. J Infect Dis,2020,222  syncytial virus following the COVID⁃19 pandemic in the
                   (Suppl 7):S577-S583                                 US[J]. JAMA Netw Open,2021,4(12):e2141779
               [30]KORSTEN K,ADRIAENSSENS N,COENEN S,et al. Bur⁃  [41]RIUS⁃PERIS J M,DEL CARMEN VICENT CASTELLÓ
                    den of respiratory syncytial virus infection in community⁃  M,LEÓN M P,et al. Changes in entire acute bronchio⁃
                    dwelling older adults in Europe(RESCEU):an interna⁃  litis seasons before,during,and after the COVID⁃19 pan⁃
                    tional prospective cohort study[J]. Eur Respir J,2021,57  demic in Spain[J]. Infect Prev Pract,2024,6(4):
                   (4):2002688                                         100399
               [31]张泰然,王 汀. 呼吸道合胞病毒及其疫苗研究进展[J].                  [42]REICHERZ F,XU R Y,ABU⁃RAYA B,et al. Waning im⁃
                    中国药剂学杂志(网络版),2025,23(1):36-43                      munity against respiratory syncytial virus during the coro⁃
                    ZHANG T R,WANG T. Research progress on respiratory  navirus disease 2019 pandemic[J]. J Infect Dis,2022,
                    syncytial virus and its vaccine[J]. Chinese Journal of  226(12):2064-2068
                    Pharmaceutical Technology(Online Edition),2025,23  [43]LI Z J,ZHANG H Y,REN L L,et al. Etiological and epi⁃
                   (1):36-43                                           demiological features of acute respiratory infections in
               [32]LIANG Y,SHAO S,LI X Y,et al. Mutating a flexible re⁃  China[J]. Nat Commun,2021,12(1):5026
                    gion of the RSV F protein can stabilize the prefusion con⁃  [44]BEWLEY K R,COOMBES N S,GAGNON L,et al. Quan⁃
                    formation[J]. Science,2024,385(6716):1484-1491     tification of SARS⁃CoV⁃2 neutralizing antibody by wild⁃
               [33]姜人月,庄忻雨,田明尧,等. 呼吸道合胞病毒mRNA候                         type plaque reduction neutralization,microneutralization
                    选疫苗的表达、鉴定及免疫效果验证[J]. 中国病原生                         and pseudotyped virus neutralization assays[J]. Nat Pro⁃
                    物学杂志,2024,19(5):497-501                            toc,2021,16(6):3114-3140
                    JIANG R Y,ZHUANG X Y,TIAN M Y,et al. Expression,  [45]GUO J Z,LU J S,DU P,et al. Fluorescence reduction neu⁃
                    identification and immune efficacy verification of a candi⁃  tralization test:a novel,rapid,and efficient method for
                    date vaccine for respiratory syncytial virus mRNA[J].  characterizing the neutralizing activity of antibodies
                    Chinese Journal of Pathogenic Biology,2024,19(5):  against dengue virus[J]. Curr Issues Mol Biol,2025,47
                    497-501                                           (3):140
               [34]CABÁN M,RODARTE J V,BIBBY M,et al. Cross⁃protec⁃  [46]程宁宁,苏彦斌,刘美琴,等. 呼吸道合胞病毒血清中和
                    tive antibodies against common endemic respiratory virus⁃  抗体检测方法的建立[J]. 微生物学免疫学进展,2024,
                    es[J]. Nat Commun,2023,14(1):798                   52(2):21-27
               [35]MAZUR N I,HORSLEY N M,ENGLUND J A,et al.            CHENG N N,SU Y B,LIU M Q,et al. Establishment of a
                    Breast milk prefusion F immunoglobulin G as a correlate  method for detecting serum neutralizing antibodies
                    of protection against respiratory syncytial virus acute  against respiratory syncytial virus[J]. Advances in Micro⁃
                    respiratory illness[J]. J Infect Dis,2019,219(1):59-67  biology and Immunology,2024,52(2):21-27
               [36]WANG Q L,LIU N L,WANG Y,et al. Antibody respons⁃  [47]WANG H J,CHEN J X,XUE L H,et al. Establishment of
                    es to respiratory syncytial virus:a population⁃based cross⁃  a pseudovirus neutralization assay for TGEV[J]. Front
                    sectional serological study in Southern China,2021[J].  Immunol,2025,16:1558604
                    Clin Microbiol Infect,2024,30(9):1183-1189   [48]COX F,SAELAND E,THOMA A,et al. RSV A2⁃based
               [37]NHAM E,JANG A Y,HYUN H,et al. Age⁃stratified sero⁃  prefusion F vaccine candidates induce RSV A and RSV B
                    prevalence of respiratory syncytial virus:analysis using  cross binding and neutralizing antibodies and provide pro⁃
                    prefusion F and G protein antibodies[J]. Vaccines(Ba⁃  tection against RSV A and RSV B challenge in preclini⁃
                    sel),2024,12(5):513                                cal models[J]. Vaccines(Basel),2023,11(3):672
               [38]LU Y F,CHEN Q H,REN S L,et al. Impact of COVID⁃19  [49] PILIPER E A,REED J C,GRENINGER A L. Clinical
                    nonpharmaceutical interventions on respiratory syncytial  validation of an RSV neutralization assay and analysis of
                    virus infections in hospitalized children[J]. Influenza  cross⁃sectional sera associated with 2021⁃2023 RSV out⁃
                    Other Respir Viruses,2024,18(4):e13291             breaks to investigate the immunity debt hypothesis[J].
               [39]UJIIE M,TSUZUKI S,NAKAMOTO T,et al. Resurgence      Microbiol Spectr,2024,12(12):e0211524
                    of respiratory syncytial virus infections during COVID⁃19  [50]LORENZO M E,HODGSON A,ROBINSON D P,et al.
                    pandemic,Tokyo,Japan[J]. Emerg Infect Dis,2021,27  Antibody responses and cross protection against lethal
                   (11):2969-2970                                      influenza A viruses differ between the sexes in C57BL/6
               [40]ZHENG Z,PITZER V E,SHAPIRO E D,et al. Estimation    mice[J]. Vaccine,2011,29(49):9246-9255
                    of the timing and intensity of reemergence of respiratory                    (下转第784页)
   152   153   154   155   156   157   158   159   160   161   162